172
Table 4.34: Distribution of Diastolic BP without anti-hypertensives,
CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median
LQ UQ
patients 90 mmHg
1997 78 606 80
70 90
73 1998 63 492
80 70
89 76
1999 98 700 76.5
67 87.5
76 2000 141
1116 80
70 88 76
Figure
4.34: Cumulative distribution of Diastolic BP without anti-hypertensives
by year
Cum u
la ti
ve d
ist ri
b u
tion
Diastolic BP, mmHg 1997
1998 1999
2000
20 40
60 80
90 100 120
140 160
.25 .5
.75 1
173
Table 4.35:
Distribution of systolic BP on anti-hypertensives CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median
LQ UQ
patients 160 mmHg
1997 391 3303
140 130
160 69
1998 456 3900
140 124
160 72
1999 478 3833
140 130
160 72
2000 497 4188
140 123
158 76
Figure 4.35: Cumulative distribution of systolic BP on anti-hypertensives by year
Cu m
u la
ti ve di
str ib
u ti
on
Sysstolic BP, mmHg 1997
1998 1999
2000
60 90
120 140
160 200
.25 .5
.75 1
174
Table 4.36: Distribution of diastolic BP on anti-hypertensives, CAPD patients,
Government Centres 1997 – 2000
Year No of
subjects No of
observations median
LQ UQ
patients 90 mmHg
1997 390 3293
90 80
90 50 1998 456
3899 86
80 90 53
1999 478 3838
88 80
90 51 2000 497
4191 85
80 90 56
Figure 4.36: Cumulative distribution of diastolic BP on anti-hypertensives by year
Cu m
u la
ti ve di
str ib
u ti
on
Diastolic BP, mmHg 1997
1998 1999
2000
20 40
60 80
90 100 120
140 160
.25 .5
.75 1
175
4.12 TREATMENT OF ANAEMIA, GOVERNMENT CAPD CENTRES Table 4.37:
Treatment for Anaemia, CAPD patients, Government Centres 1997 - 2000
Year No
on rHuEpo received
blood transfusion
received oral iron
received parenteral
iron 1997 36
28 3 86 8 1998 49
39 6 84 0 1999 396
61 23 81 13 2000 768
63 21 75 3
Table 4.38:
Distribution of rHuEpo dose per week, CAPD patients, Government Centres 1997 - 2000
Year 1997 1998 1999 2000
No. of patients 170
225 259
287 on 2000 uweek
19 25
35 31
on 2-4000 uweek 66
56 50
53 on 4-6000 uweek
2 6
3 5
on 6-8000 uweek 11
12 9
9 on 8-12000 uweek
1 1
2 3
on 12000 uweek
176
Table 4.39:
Distribution of serum Iron concentration without rHuEpo, CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ
UQ patients
10 umoll 1997 254 627
14 10
20 75 1998 190 446
15 11
24 76 1999 202 470
15 11
26 78 2000 255 549
15.8 10
23 75
Figure 4.39: Cumulative distribution of serum Iron without rHuEpo by year
Cu m
u la
ti ve di
str ib
u ti
on
serum iron, umolL 1997
1998 1999
2000
5 10
15 20
25 30
40 50
.25 .5
.75 1
177
Table 4.40: Distribution of serum Iron concentration on rHuEpo, CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ
UQ patients
10 umoll 1997 153 424
15 10
30.9 72
1998 113 323 16
11 30.3
79 1999 143 392
18 11
28 81 2000 244 557
15 10
25 73
Figure 4.40: Cumulative distribution of serum Iron concentration on rHuEpo by year.
Cu m
u la
ti ve di
str ib
u ti
on
serum iron, umolL 1997
1998 1999
2000
5 10
15 20
25 30
40 50
.25 .5
.75 1
178
Table 4.41: Distribution of serum Transferrin Saturation without rHuEpo,
CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ
UQ patients
20 1997 246 984
33.3 21.8
47.8 80
1998 158 632 35.6
22.9 49.1
78 1999 134 536
34.2 23.3
45.1 85
2000 234 936 35.3
22.4 50 80
Figure 4.41: Cumulative distribution of serum Transferrin Saturation without
rHuEpo by year
Cu m
u la
ti ve di
str ib
u ti
on
Transferrin saturation, 1997
1998 1999
2000
10 20
30 40
50 60
70 80
.25 .5
.75 1
179
Table 4.42: Distribution of serum Transferrin Saturation on rHuEpo,
CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ
UQ patients
20 1997 141 564
37.1 25
61.4 86
1998 103 412 39.3
28.1 55 88
1999 92 368 37.2
25.3 48.1
85 2000 233 932
34.1 22
49.4 82
Figure 4.42: Cumulative distribution of serum Transferrin Saturation on rHuEpo by year
Cu m
u la
ti ve di
str ib
u ti
on
Transferrin saturation, 1997
1998 1999
2000
10 20
30 40
50 60
70 80
.25 .5
.75 1
180
Table 4.43: Distribution of serum Ferritin without rHuEpo,
CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ
UQ patients
100 ugl 1997 133 193
407 217
749 86
1998 92 105 394
196 686
86 1999 124 154
482 259.7
729 93
2000 144 204 462
167.5 726.3
86
Figure 4.43: Cumulative distribution of serum Ferritin without rHuEpo by year
Cum u
la ti
ve d
ist ri
b u
tion
serum ferritin, ugL 1997
1998 1999
2000
0 50100 200 400
600 800
.25 .5
.75 1
181
Table 4.44: Distribution of serum Ferritin concentration on rHuEpo,
CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ
UQ patients
100 ugl 1997 129 216
495.5 260
994 92
1998 135 185 518
246 851
92 1999 136 201
553.3 254
857.3 93
2000 180 271 545
292.9 839.5
90
Figure 4.44: Cumulative distribution of serum Ferritin concentration on rHuEpo, by year
Cu m
u la
ti ve di
str ib
u ti
on
serumr ferritin, ugL 1997
1998 1999
2000
0 50100 200 400
600 800
.25 .5
.75 1
182
Table 4.45: Distribution of Haemoglobin concentration without rHuEpo,
CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ UQ
patients 10 gdl
patients 10 12
gdl patients
12 gdl 1997 298
981 9.1 8 10.4 67
26 7
1998 301 915
9.2 8 10.5 65 26
9 1999 336
967 9.4 8.3
10.7 61 32
7 2000
342 960 9.8 8.6
11 53 35 12
Figure 4.45: Cumulative distribution of haemoglobin concentration without rHuEpo by year
Cu m
u la
ti ve di
str ib
u ti
on
Hb, gdL 1997
1998 1999
2000
2 4
6 8
10 12
16 20
.25 .5
.75 1
183
Table 4.46: Distribution of Haemoglobin concentration on rHuEpo,
CAPD patients, Government Centres 1997 – 2000
Year No of
subjects No of
observations median LQ UQ
patients 10 gdl
patients 10 12
gdl patients
12 gdl 1997 175
652 8.7 7.3
10.1 73 22
5 1998 238
826 8.9 7.7
10.4 69 23
8 1999 262
906 8.9 7.6
10.4 69 25
6 2000 299
1013 9.3 8 10.7 62
30 9
Figure 4.46: Cumulative distribution of Haemoglobin on rHuEpo by year
Cu m
u la
ti ve di
str ib
u ti
on
Hb, gdL 1997
1998 1999
2000
2 4
6 8
10 12
16 20
.25 .5
.75 1
184
4.13 NUTRITIONAL STATUS OF CAPD PATIENTS, GOVERNMENT CENTRES Table 4.47:
